Abbott MediaRoom - Press Releases

Time 2021-01-11 23:19:34

Web Name: Abbott MediaRoom - Press Releases

WebSite: http://abbott.mediaroom.com

ID:164158

Keywords:

MediaRoom,Abbott,Releases,

Description:

Jan 11, 2021 Photos1 Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions- The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT™ Alinity™ handheld device- Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%- The test simultaneously measures biomarkers UCH-L1 and GFAP, proteins found in the blood after a concussion or head trauma- Building on this initial clearance, Abbott is also working on a test that would use whole blood on i-STAT at the point of care, and developing a test for its Alinity™ i and ARCHITECT® core laboratory instruments under FDA breakthrough designation Dec 22, 2020 Photos1 As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner- 88% of Americans say it's important for COVID-19 testing to work in support of vaccine rollout- Americans agree an authorized vaccine will not change the environment overnight, indicating a need for ongoing layered protections- Despite belief in effectiveness of vaccination and testing, there is concern that other precautionary measures will decline Dec 16, 2020 Photos3 Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform- First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes- Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter- $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process- BinaxNOW is a highly portable, easy-to-use, 15-minute antigen test with no instrument that detects the virus when people are most infectious, which is critically important in slowing the spread of the virus- Service uses Abbott's complementary NAVICA™ app to enable the testing process and display authenticated BinaxNOW test results verified by a trained guide - and supports consumer confidence in testing at home Dec 15, 2020 Photos1 Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test- SARS-CoV-2 IgG II Quant antibody test measures levels of IgG antibodies to help measure and understand a person's immune response- The test specifically identifies levels of IgG antibodies that attach to the virus' spike protein which can be helpful to evaluate a person's immune response to vaccines- CE Mark test will be available for use on Abbott's ARCHITECT® and Alinity i™ platforms- Abbott plans to submit its test for U.S. Food and Drug Administration (FDA) emergency use authorization soon Dec 14, 2020 Photos1 Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health- New product contains zinc, prebiotics and vitamins B12, C and E- Abbott expands its Pedialyte product portfolio with four new product introductions: Pedialyte with Immune Support, Pedialyte Sport, Pedialyte Organic and Pedialyte Electrolyte Water with Zero Sugar Abbott Launches First Optical Coherence Tomography Virtual Reality Training Program for CardiologistsVirtual reality training improved cath lab staff learning engagement by 45% and knowledge retention by 72%87% of studies show higher medical accuracy in medical practice by those trained with virtual reality Nearly 2 out of 3 Cardiologists Concerned about Patient’s Ability to Access Cardiovascular Care- A survey, sponsored by Abbott, reveals three in four cardiologists worry the COVID-19 pandemic has restricted heart failure patients’ ability to manage their condition- In response to COVID-19, Abbott is partnering with physicians on tools and training programs to support the diagnosis and treatment of cardiovascular disease Abbott Introduces Next-generation 3D Cardiac Mapping Platform in Europe and Australia - The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures- System offers electrophysiologists a new platform of options to provide consistent performance, regardless of the patient’s cardiac anatomy Oct 30, 2020 Photos1 Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device-- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020-- The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a leaky heart valve Oct 21, 2020 Photos1 Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance- Third-quarter sales growth of 9.6 percent; organic sales growth of 10.6 percent- Sales growth in Medical Devices and Diagnostics improved significantly versus prior quarter- Continues to strengthen portfolio with several recent new product approvals, including FreeStyle Libre 3, Libre Sense Glucose Sport Biosensor and MitraClip G4 heart device Oct 19, 2020 Photos1 Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows- New research from the University of Illinois, Urbana-Champaign, Abbott, and U.S. Air Force published in the journal Scientific Reports demonstrates that the right nutrition is directly linked to physical and cognitive performance in active duty men and women in the U.S. Air Force- Research subjects from the U.S. Air Force, who consumed a specialized nutrition drink with key nutrients, showed an 11% improvement in working memory, resulting in better information processing, problem-solving and multitasking skills- When nutrition was combined with an exercise regimen, study participants showed statistically significant improvements in 80% of key fitness and cognition metrics measured New Late-Breaking Data Show Equivalent Outcomes with Shorter Durations of Anti-Clotting Drugs for XIENCE™ Stent Patients with High Bleeding Risk - Results from Abbott’s XIENCE™ 28 and XIENCE 90 trials demonstrate non-inferiority of shorter courses of dual antiplatelet therapy in reducing the frequency of post-stenting death, heart attacks and severe bleeding compared with 12 months of dual antiplatelet therapy in patients with high bleeding risk - Late-breaking data confirm the consistent effect of XIENCE stent technology, when applied to complex, high bleeding risk patients Oct 12, 2020 Photos1 Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test- Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset- Availability of the new IgM blood test on the ARCHITECT® and Alinity™ platforms is part of Abbott's effort to offer tests across the disease progression of COVID-19- Abbott's IgM test will give a more complete picture of where patients are in their recovery Oct 7, 2020 Photos1 Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health- Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset- ID NOW is the most studied COVID-19 test available; interim post-authorization study evaluated 1,003 people- To date, Abbott has shipped more than 12 million ID NOW tests to all 50 states and provided more than 30 million rapid and lab-based COVID-19 tests in the U.S. since March Abbott Enrolls First Patient in Study to Investigate BurstDR™ Stimulation to Treat Non-operative Low Back Pain - Low back pain affects one in 10 Americans and often impacts the patient physically, emotionally and economically - The multicenter, randomized, controlled DISTINCT study represents an Abbott collaboration with both spine surgeons and pain specialists to amass post-market evidence for its BurstDR™ spinal cord stimulation therapy for patients who have limited surgical options Sep 28, 2020 Video1Photos3 Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people with diabetes- With the smallest and thinnest[3] wearable glucose sensor (about the size of two stacked U.S. pennies), FreeStyle Libre 3 users can view their glucose levels discreetly[4] and conveniently,[5] anytime[6]- Building on the proven FreeStyle Libre 2 sensor performance with a new sensor design at the same affordable price as previous versions,[7] the FreeStyle Libre 3 system is the latest innovation of Abbott's world-leading[8] continuous glucose monitoring technology Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. You are about to exit for another Abbott country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. The website you have requested also may not be optimized for your specific screen size. Do you wish to continue and exit this website? You are about to exit the Abbott family of websites for a 3rd party website Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size. Do you wish to continue and exit this website?

TAGS:MediaRoom Abbott Releases 

<<< Thank you for your visit >>>

Hot Websites